research

Our Achievements and capabilities

13

first time
launches

253

patents filed
(162 approved)

6

biologics including
one new indication

117

DMFs filed

5 NDDS

launches with half a
dozen more in the pipeline

1500+

dossiers filed globally
in the last two decades

48

research publications

These achievements give a fair snapshot of the excellence that Emcure’s research and development team has been able to deliver.

Being one of the top pharmaceutical manufacturing companies in India, Emcure Pharmaceuticals is focused on delivering cutting-edge research with the help of its expertise in complex API, multiple dosage form development, bio-therapeutics and mRNA development. The research & development efforts of Emcure Pharmaceuticals are dedicated towards development of differentiated formulations, sophisticated characterization of complex molecules and product & process improvement to achieve better quality and productivity.

With a strong biopharma platform, Emcure intends to develop biologics with a focus on both microbial and mammalian lines. In its endeavor to build a growing vaccine pipeline based on the in-house developed mRNA platform, Emcure intends to build its portfolio in vaccines and use the mRNA platform to develop other biologics.

The research & development team at Emcure is comprised of close to 500 highly qualified scientists (53 PhD) and the activities are spread across its five dedicated facilities, located in Pune and Ahmedabad. One of these is dedicated to API research, one towards Biotechnology research while four are dedicated to formulations research. With Emcure’s state-of-the-art research centers, sophisticated equipment’s, talented R&D team and strong focus towards innovation, the Pune University has accredited Emcure’s research and development center as a PhD center for prospective students to complete their thesis/research.

The in-house regulatory affairs units of Emcure Pharmaceuticals has significant expertise in filing product dossiers with regulators in the United States, the European Union, WHO-PQ and other jurisdictions and is capable of submitting DMFs, ANDAs and Marketing Authorizations in common technical document (CTD) format.